Skip to main content
. 2020 Jun 9;10(4):829–851. doi: 10.1016/j.jcmgh.2020.06.001

Figure 1.

Figure 1

Characterization of ACC inhibition by PF-05221304. (A) Chemical structure of PF-05221304. (B) Reversibility of PF-05221304 binding by dilution. (C) Lineweaver–Burk analysis of PF-05221304 with ATP as the varied substrate. (D) Lineweaver–Burk analysis of PF-05221304 with carbonate as the varied substrate. (E) Lineweaver–Burk analysis of PF-05221304 with acetyl-CoA as the varied substrate. (C–D) Open circles, uninhibited; squares, 3 nmol/L PF-05221304; triangles, 10 nmol/L PF-05221304; reverse triangles, 30 nmol/L PF-05221304. (F and G) Inhibition dose curves for (F) rat and (G) human ACC isoforms. ACCi, PF-05221304.